THE PSCI PRESENTS ITS SECOND PUBLIC AUDIT FINDINGS REPORT, PROVIDING CONTINUED INSIGHTS INTO SUPPLIER RISKS, TRENDS, AND AREAS FOR IMPROVEMENT ACROSS THE PHARMACEUTICAL AND HEALTHCARE SUPPLY CHAIN.

This report shares our analysis of findings from PSCI audits available on our platform. Each year, we review these in line with the PSCI Principles to identify trends, highlight improvements, and share recommendations. Overall, this analysis provides deep insight into supplier practices within the pharmaceutical and healthcare industry and guides us on developing targeted resources and trainings.

The year’s report analyzes 1,776 findings from 180 supplier audits uploaded to the PSCI platform in 2023. These findings are categorized into 308 Management Systems findings, 7 Ethics findings, 169 Human Rights findings, 970 Health & Safety findings, and 322 Environment findings, offering a comprehensive overview of supplier practices and opportunities for improvement. The report includes a summary of findings across key topics, detailed breakdowns with recommended actions for suppliers, and links to relevant

What’s new this year?

• The first-ever analysis by supplier type, providing tailored insights into specific supplier categories.
• A regional analysis focused on major pharmaceutical manufacturing hubs, including China and India.
• A deep-dive analysis of 13 suppliers’ audit data over three years, exploring changes in supplier practices and measuring PSCI’s impact.

The report reinforces the PSCI’s role as a catalyst for continuous improvement, equipping suppliers with tools and guidance to enhance practices and adapt to evolving demands. For more details, access the full report in the resource attached.